<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-001597
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20070330
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20070405
<DATE-OF-FILING-DATE-CHANGE>20070405
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>07752648
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
<PHONE>4849131200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w32891e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED
STATES<br>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>Date of Report (Date of earliest event reported): March&nbsp;30, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><FONT style="border-bottom: 1px solid #000000"><B>NOVAVAX, INC.</B></FONT>
</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><B>(Exact name of Registrant as specified in its charter)</B></DIV></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" nowrap><B>(State or other jurisdiction
of incorporation or</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(I.R.S. Employer Identification No.)</B></TD>
</TR>


<TR valign="bottom">
    <TD align="center" valign="top"><B>organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>



<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" colspan="2"><B>9920 Belward Campus Drive <BR>
Rockville, Maryland<BR>
(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850<BR>
(Zip Code)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" colspan="2" nowrap><B>Registrant&#146;s telephone number, including area code:</B>
</TD>
    <TD>&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(240)&nbsp;268-2000</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Not applicable</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Former name or former address, if changed since last report.)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant<BR>
under any of the following provisions (see General Instruction A.2. below):</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</B>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt">
<B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of  Certain Officers; Compensatory Arrangements of Certain Officers.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
On March 30, 2007, Jeffrey W. Church resigned as the Chief Financial Officer of
Novavax, Inc., (the &#147;Company&#148;) effective April&nbsp;20, 2007.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
In connection with Mr. Church&#146;s resignation, on April&nbsp;5, 2007, Len Stigliano was appointed to serve as the Interim
Chief Financial Officer of the Company.  Mr. Stigliano will commence employment on April&nbsp;11, 2007 but will not become
Interim Chief Financial Officer until April&nbsp;20, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Mr. Stigliano is 59 years old and a partner at Tatum, LLC, an executive services firm and will
serve as the Interim Chief Financial Officer of the Company though an Interim Executive Services Agreement
between the Company and Tatum, LLC.  Mr. Stigliano has served as a partner of the Philadelphia office
of Tatum, LLC from December 2006 to the present. Mr. Stigliano was president and chief operating
officer at Omnicare Clinical Research, a global clinical research organization from 2000 until December 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Pursuant to the Amended Executive Services Agreement, Mr. Stigliano will receive a salary of $21,600 per month.  Mr. Stigliano will
be eligible to receive cash bonuses upon the achievement of certain goals. Mr. Stigliano will not be entitled to
any option or equity grants or participate in any Company- sponsored health plans.  Mr. Stigliano will be
entitled to participate in the Company&#146;s employee retirement and/or 401(k) plans and to vacation and holidays
consistent with the Company's policy for senior management who are employed full time.  Mr. Stigliano also will
be entitled to coverage under the Company&#146;s liability insurance policy for directors and officers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
As compensation for the engagement of Mr. Stigliano, beginning on April&nbsp;11, 2007, the Company will pay Tatum, LLC
an $5,400 per month and will receive bonus payments if Mr. Stigliano receives bonus payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
The Company issued a press release on April&nbsp;5, 2007 announcing the resignation of Mr. Church as Chief Financial
Officer and appointment of Mr. Stigliano as the Company&#146;s Interim Chief Financial Officer, a copy of
which is attached hereto as Exhibit 99.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 16pt">
<B>Item 9.01.  Financial Statements and Exhibits.</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
(d) Exhibits
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	99.1	Press Release of the Company dated April 5, 2007
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">Novavax, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">(Registrant)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">April&nbsp;5, 2007
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>

    <TD align="left" valign="top" colspan="2">/s/ Rahul Singhvi
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>

    <TD align="left" valign="top" colspan="2">Rahul Singhvi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>

    <TD align="left" valign="top" colspan="2">President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w32891exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT&nbsp;99.1</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 6pt">
<B>NOVAVAX APPOINTS INTERIM CFO</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">
<B>Jeffrey W. Church Resigns as Chief Financial Officer </B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 26pt">
<B>ROCKVILLE, MD</B> (April 5, 2007) &#150; Novavax Inc. today appointed Len Stigliano as interim Chief Financial Officer to
replace Jeffrey W. Church, who is leaving later this month to accept a position with another company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
&#147;We are very disappointed to lose Jeff, but we respect his personal decision,&#148; said Novavax President and Chief
Executive Officer Dr. Rahul Singhvi.  &#147;I am confident that Len has the experience to serve the company well until
a permanent replacement is found.&#148;  Dr. Singhvi said a formal search would begin immediately.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Stigliano, a partner in the Philadelphia office of the executive services firm Tatum LLC, has held CFO and general
management positions in a number of publicly traded life sciences companies.  A graduate of Rutgers University with
an MBA from Pace University, Stigliano began his career in 1975 at USV Pharmaceuticals, which was part of Revlon&#146;s Healthcare Group.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
More recently, Stigliano was president and chief operating officer at Omnicare Clinical Research, a global clinical
research organization.   Prior to Omnicare, he served as chief financial officer of IBAH Inc., which was acquired by Omnicare in 1998.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
<B>About Novavax</B><br>
Novavax Inc. (NASDAQ: NVAX) is committed to leading the global fight against infectious disease by creating
novel, highly potent vaccines that are safer and more effective than current preventive options. Using the
company&#146;s proprietary virus-like particle (VLP) and
Novasome&#174; adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza,
seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing
viruses while lacking the genetic material to cause disease, which provides potential for greater
immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid
mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
